Similarly, the motif chemokine (CXC) chemokine receptor (CXCR2) antagonist Z10397767 attenuated interleukin-8 (IL-8) induced c-FLIP(S) up-regulation in prostate cancer cell lines thus enhancing sensitivity of these cells to TRAIL-chemotherapy [142], and thioridazine increased susceptibility of head and neck squamous cell carcinoma cells (AMC-HN4) to carboplatin through downregulation of c-FLIP and Mcl-1 expression [143]. Here, CXCL8 is linked to prostate carcinoma.